Identification of lipid biomarker from serum in patients with chronic obstructive pulmonary disease

Respiratory Research

Pierre Massion¹  Shuaishuai Wang²  Peng George Wang²  Lei Li²  Ding Liu²  Shiying Zhang²  Maureen Meister³  Xiangming Ji³  Ruixie Fang⁴  Chi-In Vong⁵ 

[1] Cancer Early Detection and Prevention Initiative, Vanderbilt Ingram Cancer Center; Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, 37232, Nashville, TN, USA;Department of Chemistry, Georgia State University, 30303, Atlanta, GA, USA;Department of Chemistry, Georgia State University, 30303, Atlanta, GA, USA;Department of Nutrition, Georgia State University, 30302, Atlanta, USA;Department of Mathematics and Statistics, Georgia State University, 30302, Atlanta, GA, USA;Department of Nutrition, Georgia State University, 30302, Atlanta, USA;

关键词: Chronic obstructive pulmonary disease (COPD);    Lipidomics;    Biomarkers;    OPLS-DA;    Receiver operating characteristic;   

DOI  :  10.1186/s12931-020-01507-9

来源: Springer

【 摘 要 】

BackgroundChronic obstructive pulmonary disease (COPD) is the third leading cause of death in the United States with no effective treatment. The current diagnostic method, spirometry, does not accurately reflect the severity of COPD disease status. Therefore, there is a pressing unmet medical need to develop noninvasive methods and reliable biomarkers to detect early stages of COPD. Lipids are the fundamental components of cell membranes, and dysregulation of lipids was proven to be associated with COPD. Lipidomics is a comprehensive approach to all the pathways and networks of cellular lipids in biological systems. It is widely used for disease diagnosis, biomarker identification, and pathology disorders detection relating to lipid metabolism.MethodsIn the current study, a total of 25 serum samples were collected from 5 normal control subjects and 20 patients with different stages of COPD according to the global initiative for chronic obstructive lung disease (GOLD) (GOLD stages I ~ IV, 5 patients per group). After metabolite extraction, lipidomic analysis was performed using electrospray ionization mass spectrometry (ESI-MS) to detect the serum lipid species. Later, the comparisons of individual lipids were performed between controls and patients with COPD. Orthogonal projections to latent structures discriminant analysis (OPLS-DA) and receiver operating characteristic (ROC) analysis were utilized to test the potential biomarkers. Finally, correlations between the validated lipidomic biomarkers and disease stages, age, FEV1% pack years and BMI were evaluated.ResultsOur results indicate that a panel of 50 lipid metabolites including phospholipids, sphingolipids, glycerolipids, and cholesterol esters can be used to differentiate the presence of COPD. Among them, 10 individual lipid species showed significance (p < 0.05) with a two-fold change. In addition, lipid ratios between every two lipid species were also evaluated as potential biomarkers. Further multivariate data analysis and receiver operating characteristic (ROC: 0.83 ~ 0.99) analysis suggest that four lipid species (AUC:0.86 ~ 0.95) and ten lipid ratios could be potential biomarkers for COPD (AUC:0.94 ~ 1) with higher sensitivity and specificity. Further correlation analyses indicate these potential biomarkers were not affected age, BMI, stages and FEV1%, but were associated with smoking pack years.ConclusionUsing lipidomics and statistical methods, we identified unique lipid signatures as potential biomarkers for diagnosis of COPD. Further validation studies of these potential biomarkers with large population may elucidate their roles in the development of COPD.

【 授权许可】

CC BY